Skip to main content
. 2018 Jun 8;218(Suppl 5):S545–S552. doi: 10.1093/infdis/jiy267

Figure 4.

Figure 4.

Protective efficacy against lethal mouse-adapted Ebola virus (MA-EBOV) challenge. Mice (groups of 5) were vaccinated twice at 4-week intervals by microneedle (MN) patch delivery (sGPadj-MN) or intramuscular (IM) injection (sGPadj-IM) of soluble glycoprotein (sGP) in formulation with Matrix-M or by MN patch delivery (sGP-MN) or IM injection (sGP-IM) of the same amount (5 µg) unadjuvanted sGP. The control mice received IM injection of phosphate-buffered saline. At 8 weeks after the second immunization, mice were challenged by intraperitoneal injection with 1000 plaque-forming units of MA-EBOV and monitored daily for survival, body weight changes, and disease symptoms. (A) Daily survival rate of mice in each group postchallenge. Statistical analysis of the Kaplan-Meier survival curves after challenge was conducted by log-rank analysis (P = .0113). (B) Average body weight of surviving mice in each group were determined daily postchallenge and expressed as the percentage of the average body weight of the same group of mice on day 0 of challenge. (C) Average daily clinical scores of surviving mice in each group postchallenge. Clinical scores were recorded as described in Methods.